Navigation Links
Pregis Announces First Quarter 2008 Financial Results
Date:5/9/2008

weakened economic environment and to solidify our foundation for future growth."

For the first quarter of 2008, operating income was $8.3 million compared to $16.5 million in the first quarter of 2007, with the reduction driven primarily by increased raw material costs, as noted above.

Segment Performance

Comments on segment net sales performance for the first quarter of 2008 are as follows:
-- Net sales of the protective packaging segment increased by $12.8

million, or 8.2%. The 2008 first quarter sales growth was driven by

favorable foreign currency translation, as well as the incremental

sales generated by the Petroflax and Besin entities acquired in the

second half of 2007. The segment experienced declining volumes in

both its U.S. and European businesses due primarily to the weakened

U.S. and European economies. Excluding the impact of favorable

foreign currency effects and acquisitions, net sales for the segment

decreased 3.8%.

-- Net sales of the flexible packaging segment increased $5.6 million,

or 13.1%. Improvements in pricing and product mix were offset by

volume shortfalls in the segment's Egyptian operations. Excluding

the impact of favorable foreign currency, 2008 net sales for the

segment were comparable to the 2007 period.

-- Net sales of the hospital supplies segment increased $2.3 million,

or 11.9%. Excluding the impact of favorable foreign currency

effects, net sales for the segment decreased 2.1% in the quarter,

primarily due to price erosion resulting from the competitive market

environment.

-- Net sales of the rigid packaging segment were relatively flat

compared to net sales in the first quarter of 2007. However,

excluding the impact of favorable foreign currency effect
'/>"/>

SOURCE Pregis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Pregis Corporation Appoints New President of Protective Packaging North America
2. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
3. Pregis Announces Fouth Quarter and Full Year 2007 Financial Results
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)..., May 16 /PRNewswire/ -- Law Offices of Howard G. ...o be a lead plaintiff in the,securities class acti...hased or otherwise acquired the common stock of In...cal" or the "Company") (Amex: IMA ) in the,Compan... 14, 2007 (the,"Class Period"). The shareholder la...
(Date:5/16/2008)...eport side effects, but critics want agency to act...lthDay News) -- Direct-to-consumer drug ads on tel...at would allow consumers to report adverse side ef...The experts serve on a panel that advises the U.S....are already mandated by the FDA for print ads. At ...
(Date:5/16/2008)...rs More than 500 Workers, WASHINGTON, May 16 /PRN...d emergency medical technicians in the Greater Por...ratified their first-ever contract as,Teamsters., ... now covered by a,strong contract that gives them ...id Teamsters General President Jim Hoffa., The wo...
(Date:5/16/2008)...ic disease sufferers gain benefit from calcitriol,...Day News) -- Taking activated vitamin D may cut th... chronic kidney disease by about one quarter, a ne... more than 1,400 patients, those being treated wit... had their overall risk of death lowered by 26 per...
Breaking Medicine News(10 mins):Health News:Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc. 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
... is certain to increase and a new research program...population increases, so does the incidence of chr...gh coping with dementia in the West, where the con...rying to cope in a developing country, where there...
...cer of the oesophagus may improve the outcome of t...ading from the throat to the stomach - affects 500...st common cancer. The main problem is spread of th... for doctors to know which gland close to the oeso...
...erol levels are controlled by both genes and dieta... often advised to go on a low-fat diet - or to tak...cing fat intake can reduce cholesterol levels. But...l hypercholesterolaemia (FH) which leads to high c...
...l of Medicine, twelve people were hospitalized for...mushrooms, and three of them died, wrote Dr. Regis... Pellegrin in Bordeaux, France.Bedry said he confi...to mice and measuring creatine kinase, an enzyme p...
Other Medicine News:
(Date:5/15/2008)...ostate, Colorectal and Ovarian ...Event on Sun., June 1 with Oncology Experts -, SO...tCall/ -- Poniard,Pharmaceuticals, Inc. (Nasdaq: ...ology, today announced that the Company will prese...in various tumor types and combinations, at,poster...
(Date:5/15/2008)...lects depth and breadth of, collaboration with in...r diverse forms of cancer ...), the leading IV, bisphosphonate, on relapse rate...ur oral sessions to feature RAD001, first oral onc...irst results of RECORD-1 study in renal cell ...
(Date:5/15/2008)...rstCall/ -- Sanofi-aventis,(EURONEXT: SAN and NYSE...mark ATHENA study showed Multaq(R) (dronedarone), ...with atrial fibrillation or atrial flutter,decrea... death from any,cause by a statistically significa...ndpoint. The ATHENA results will be presented at t...
(Date:5/15/2008)...re/ -- Ergonex Pharma today,announced that the Uni...granted orphan drug designation to Terguride for t...AH). Terguride is currently being evaluated for PA...A,s grant of orphan drug designation to Terguride ... program by offering regulatory,clinical developm...
Breaking Medicine Technology:Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 1CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 8Tips for Troublesome Medications From the Harvard Heart Letter 12794 1Tips for Troublesome Medications From the Harvard Heart Letter 12794 2ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3533 1ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3533 2ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3533 3CMC Moffitt Partner to Study Cancer 1435 1CMC Moffitt Partner to Study Cancer 1435 2
...-Having a build-up of calcium,plaque in the arteri... from heart disease in multiple ethnic groups, acc... of Atherosclerosis (MESA),funded by the National ...nstitutes of Health. Previous studies have shown t... greater risk of,heart disease events and deaths i...
...ar 26, 2007 - Two-year results from,the Medtronic ...,clinical profile of the Endeavor(R) drug-eluting ...r of Endeavor patients who have at,least two years...deavor patients, there have been no reported cases...re-specified clinical trial,protocol definitions f...
Other Medicine Technology:Calcium Plaque Build-up in the Arteries Leads to Coronary Heart,Disease in Multi-Ethnic Groups 2Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 2Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 3
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: